Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan

CONCLUSIONS: Approximately half the patients in both the luminal-type and triple-negative groups were prescribed anthracycline and/or taxane for perioperative chemotherapy. The choice was associated with patient age, cancer stage, and the scale and specialization of the treatment facilities. This study sheds light on the current state of breast cancer treatment practices in Japan.PMID:38679657 | DOI:10.1007/s12282-024-01572-8

Source: Breast Cancer - April 28, 2024 Category: Cancer & Oncology Authors: Akihiko Shimomura Yasuaki Sagara Ryo Koto Masakazu Fujiwara Yuka Kanemura Hiroshi Kitagawa Shigehira Saji Source Type: research